Caffeine and incidence of dyspnea in patients treated with ticagrelor
Daniel Lindholm(AstraZeneca (Finland)), Christoph Varenhorst, Susanne Heller, Patrik Öhagen, Oscar Ö. Braun(Lund University), Jonas Andersson(Skellefteå Hospital), Peter Henriksson(Karolinska Institutet), Stefan James(Uppsala University), Jörg Lauermann(Karolinska University Hospital)
Cited by 5
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
|European Heart Journal|2024|2.4k
2024 ESC Guidelines for the management of chronic coronary syndromes
|European Heart Journal|2024|2.3k